Advertisement

Topics

Companies Related to "PenicillinBinding Proteins PBPs Inhibitors Pipeline Insights 2017 Updated" [Most Relevant Company Matches] RSS

04:40 EST 21st November 2018 | BioPortfolio

Here are the most relevant search results for "PenicillinBinding Proteins PBPs Inhibitors Pipeline Insights 2017 Updated" found in our extensive corporate database of over 50,000 company records.

Showing "PenicillinBinding Proteins PBPs Inhibitors Pipeline Insights 2017 Updated" Companies 1–25 of 2,100+

Relevant

Inflection Biosciences Ltd

Inflection Biosciences Ltd, based in Dublin and London, is developing small molecule therapeutics for the treatment of cancer. The company's pipeline of highly innovative cancer treatments was licensed from the Spanish National Cancer Research Centre (CNIO). The pipeline comprises the IBL-300 series (PIM/PI3K/mTOR inhibitors) and IBL-202 (PIM/PI3K inhibito...


BIOPUR AG

BIOPUR manufactures highly purified proteins and enzymes derived from human and animal sources for research use. Our focus is the extraction of proteins and enzymes from native plasma and other sources. We also offer customized purification of very rare proteins in larger quantities. Some examples of our product line are coagulation factors like Thrombin, extra-cellular-martix (ECM) proteins for c...

Akari Therapeutics Plc

Akari is a clinical-stage biopharmaceutical company focused on the development and commercialization of life-transforming treatments for a range of rare and orphan autoimmune and inflammatory diseases caused by dysregulation of complement C5 and Leukotriene B4 (LTB4), including paroxysmal nocturnal hemoglobinuria (“PNH”), atypical Hemolytic Uremic ...


Ocugen, Inc.

Ocugen is advancing novel biologicals discovered based on endogenous proteins with well understood biology at the molecular, cellular, and whole animal level to treat eye diseases. The therapeutic proteins in the pipeline are derived from cell survival factors such as lens epithelium derived growth factor (LEDGF) and anti-angiogenic proteins such as tumsta...

QIAGEN GmbH

QIAGEN N.V., a Netherlands-based holding company, is the leading global provider of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. Our sample technologies isolate and process DNA, RNA and proteins from blood, tissue and other materials. Assay technologies make these...

KalVista Pharmaceuticals, Inc.

KalVista Pharmaceuticals, Inc. is a pharmaceuticals company focused on the discovery, development, and commercialization of small molecule protease inhibitors for diseases with significant unmet need. The initial focus is on inhibitors of plasma kallikrein, which is an important component of the body’s inflammatory response and which, in excess, can l...

QIAGEN N.V.

QIAGEN N.V., a Netherlands-based holding company, is the leading global provider of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. Our sample technologies isolate and process DNA, RNA and proteins from blood, tissue and other materials. Assay technologies make these...

Palleon Pharmaceuticals

Palleon Pharmaceuticals is the leading biotechnology company focused on developing Glycoimmune Checkpoint inhibitors to treat cancer. The company’s proprietary Convergence Platform integrates technologies and insights from world-renowned scientific leaders in the fields of glycoscience and human immunology to create a novel approach to treating cancer...

Amura Holdings Ltd

Amura has two complementary technology platforms which enable rapid and innovative drug discovery. AMcore™, the bicyclic core molecular scaffold chemistry and the computational screening and design platform, ProtoDiscovery™. Amura has four NCE discovery programmes based on AMcore™:An Osteoporosis programme based on cathepsin K inhibitors, A Psoriasis programme based on a cathepsin S inhibit...

Haematologic Technologies, Inc

Haematologic Technologies, Inc. (HTI) is a primary manufacturer that specializes in the isolation and characterization of high quality, human plasma proteins which are intended for in vitro research use. HTI’s emphasis is focused on proteins involved in the regulation of blood coagulation and fibrinolysis, as well as the regulation of bone metabolism. The HTI product line consists of over 150 hi...

Proteolix, Inc.

Founded in December 2003, Proteolix, Inc. is a privately-held biotechnology company, headquartered in South San Francisco, dedicated to discovering, developing and commercializing novel therapeutics that target protein degradation pathways for cancer and autoimmune diseases. Proteolix's lead product, carfilzomib, is the first in a new class of selective, irreversible proteasome inhibitors. Prote...

Kinex Pharmaceuticals, LLC

Kinex Pharmaceuticals is developing next generation anti-cancer drugs that target the molecular basis of disease. The Company uses a proprietary technology platform to generate compounds that inhibit the Protein Kinase and Phosphatase family of proteins.Protein kinases and phosphatases are families of proteins that are intimately involved in transmitting signals across the cell membrane. They cont...

Five Prime Therapeutics

Five Prime Therapeutics, Inc. is a clinical-stage biotechnology company focused on discovering and developing novel protein therapeutics for cancer and inflammatory diseases. Five Prime has developed a library of more than 5,600 human extracellular proteins. Five Prime screens this comprehensive library with its proprietary high-throughput protein screening technologies to identify new targets f...

ILEX Oncology

Based in San Antonio, Texas, ILEX has a marketed product, Campath®, a treatment for patients with refractory chronic lymphocytic leukemia. ILEX is also advancing a robust pipeline of oncology product candidates. The pipeline comprises multiple technologies at all stages of clinical development, including a monoclonal antibody, apoptosis-inducing agents, cytotoxic compounds with novel mechanisms o...

FLX Bio, Inc.

FLX475 is a best-in-class oral, small molecule antagonist of CCR4. CCR4 ligands are elevated in multiple tumor types when compared to normal tissue. In preclinical studies, FLX475 inhibited tumor growth and increased tumor regression. In addition, FLX475 enhanced the antitumor effects of various checkpoint inhibitors including anti-PD-L1 and anti-CTLA4 ant...

Scil Proteins

Scil Proteins is a biopharmaceutical company working with industry partners in the development and manufacture of protein therapeutics and diagnostics as well as discovering and developing proprietary Affilin® molecules. The Company has a longstanding expertise in protein production and development and offers GMP contract biomanufacturing and process de...

Ayala Pharmaceuticals

Ayala Pharmaceuticals is a clinical-stage biopharmaceutical company dedicated to developing targeted cancer therapies for people living with genetically defined cancers. The company was founded in November 2017 with an experienced global management team and a strong investor base. The management bench recently expanded with the appointment of Andrea Vergar...

ZymoGenetics

For more than 25 years, ZymoGenetics has focused on the discovery, development, and commercialization of therapeutic proteins. Thanks to a robust discovery program, promising drug pipeline and strong development capabilities, ZymoGenetics is an emerging leader among biotherapeutic companies. ZymoGenetics is: Dedicated to the development of protein drugs. We are committed to developing protein dru...

Capitol Insights

Capitol Insights helps organizations develop and implement comprehensive public relations and government affairs programs to educate the public, motivate people and shape public policy.Capitol Insights helps clients understand how policy may move in the future because of changes in public opinion, political pressure and legal interpretation. Helping organizations make better decisions and build st...

NAM Asia Hong Kong Co., Ltd.

CEO Teppei Nakano graduated from Keio University School of Medicine in 2017. We have been adopting IPA unexplored projects by the Ministry of Economy, Trade and Industry, which represent a large number of representatives of IT companies representing Japan, twice in 2016 and 2017, independent businesses that have been adopted by unexplored This is the NAM p...

Isarna Therapeutics GmbH

Isarna Therapeutics has an unmatched commitment to developing TGF-β inhibitors that stimulate the human immune system to effectively fight cancer. Isarna Therapeutics are advancing a unique pipeline of novel oligonucleotides and combination modalities to transcend clinical response and improve patient outcomes.  The role of tgf-beta in cancer The cytokine human transforming growth ...

CellZome AG

Cellzome is a privately-owned drug discovery company identifying a new generation of kinase- targeted drugs to treat inflammatory diseases. Its pipeline of small-molecule therapeutics is driven by Kinobeads™, a proprietary technology for the screening and profiling of kinases in relevant cells and tissues. Cellzome's emerging pipeline includes a small molecule Histamine H4 receptor antagonist, ...

Transcend Insights and Humana Inc.

Transcend Insights, the population health technology company of Humana Inc. (NYSE: HUM), provides solutions that rise above data silos and connect care teams with the insights they need to succeed in a value-based care world. By leveraging its leading-edge approach to data aggregation, interoperability and analytics, Transcend Insights provides health syst...

NewEast Biosciences

NewEast Biosciences are specialized in generating protein configuration-specific monoclonal antibodies that recognize active (GTP-bound) G proteins (including Ras-superfamily small GTPases and heterotrimeric G proteins). These unique antibodies do not recognize the inactive (GDP-bound) G proteins. These monoclonal antibodies have been successfully used to immunoprecipitate active G proteins...

AvidBiotics Corp.

AvidBiotics is developing two proprietary platforms for the generation of non-antibody proteins against infectious diseases and cancers: Avidocin™ proteins and Micacide™ proteins.


More From BioPortfolio on "PenicillinBinding Proteins PBPs Inhibitors Pipeline Insights 2017 Updated"

Advertisement
Quick Search
Advertisement
Advertisement

 

Corporate Database Quicklinks